Literature DB >> 8363761

Sentinel surveillance for HIV-1 among pregnant women in a developing country: 3 years' experience and comparison with a population serosurvey.

R M Kigadye1, A Klokke, A Nicoll, K M Nyamuryekung'e, M Borgdorff, L Barongo, U Laukamm-Josten, F Lisekie, H Grosskurth, F Kigadye.   

Abstract

OBJECTIVES: To establish unlinked, anonymous sentinel surveillance for HIV-1 among pregnant women attending an antenatal clinic, to determine age-specific seroprevalences, to monitor trends and to compare seroprevalence with that detected by a population serosurvey. To establish the sustainability and costs of surveillance.
DESIGN: Sentinel surveillance for HIV through serial collection of unlinked, anonymous seroprevalence data from antenatal care; comparison of sentinel data with those from a population serosurvey; financial and general audit of the sentinel surveillance.
SETTING: A community antenatal clinic in a large urban centre, Mwanza Municipality, Tanzania, eastern Africa, between October 1988 and September 1991. PATIENTS: Pregnant women attending for antenatal care. MAIN OUTCOME MEASURE: Age-specific HIV-1 seroprevalences, trends over time, difference from age-specific population seroprevalences, sustainability and costs.
RESULTS: Overall HIV-1 seroprevalence was 11.5% (95% confidence interval, 10.5-12.4); differences in age-specific prevalences were not significant. There was no clear evidence of change in seroprevalence over the study period in any age group, although there was some indication of a rise in some age groups in 1988-1989. Sentinel surveillance among pregnant women may have significantly underestimated population HIV-1 seroprevalence for women under the age of 35 years. HIV-1 surveillance proved feasible and sustainable. Additional recurrent costs were US$1.7 per specimen for unlinked anonymous testing and US$0.57 per woman for syphilis screening.
CONCLUSIONS: HIV-1 seroprevalence did not change significantly over 3 years, probably implying a substantial incidence of HIV-1 infection. In this setting seroprevalence in pregnant women may have underestimated population seroprevalence in women aged under 35 years. With modest inputs and good organization unlinked anonymous HIV-1 sentinel surveillance of pregnant women can be introduced and sustained in an African setting. This may usefully be carried out in conjunction with syphilis screening.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Biology; Demographic Factors; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Epidemiologic Methods; Examinations And Diagnoses; Hematologic Tests; Hemic System; Hemoglobin Level; Hiv Infections; Hiv Serodiagnosis--cost; Infections; Laboratory Examinations And Diagnoses; Laboratory Procedures; Measurement; Physiology; Population; Population Characteristics; Pregnant Women; Prevalence; Reproductive Tract Infections; Research Methodology; Research Report; Sampling Studies; Screening--cost; Sexually Transmitted Diseases; Studies; Surveys--cost; Syphilis; Tanzania; Viral Diseases

Mesh:

Substances:

Year:  1993        PMID: 8363761     DOI: 10.1097/00002030-199306000-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  HIV and population dynamics: a general model and maximum-likelihood standards for east Africa.

Authors:  Patrick Heuveline
Journal:  Demography       Date:  2003-05

2.  HIV prevalence and sexual behaviour changes measured in an antenatal clinic setting in northern Tanzania.

Authors:  M Urassa; Y Kumogola; R Isingo; G Mwaluko; B Makelemo; K Mugeye; T Boerma; T Calleja; E Slaymaker; B Zaba
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

3.  Hotspots and Coldspots: Household and village-level variation in orphanhood prevalence in rural Malawi.

Authors:  Alexander Weinreb; Patrick Gerland; Peter Fleming
Journal:  Demogr Res       Date:  2008-07-15

4.  Refusal bias in HIV prevalence estimates from nationally representative seroprevalence surveys.

Authors:  Georges Reniers; Jeffrey Eaton
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

5.  Comparison of STD prevalences in the Mwanza, Rakai, and Masaka trial populations: the role of selection bias and diagnostic errors.

Authors:  K K Orroth; E L Korenromp; R G White; J Changalucha; S J de Vlas; R H Gray; P Hughes; A Kamali; A Ojwiya; D Serwadda; M J Wawer; R J Hayes; H Grosskurth
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

6.  Risk factors associated with low CD4+ lymphocyte count among HIV-positive pregnant women in Nigeria.

Authors:  Alash'le Abimiku; Pacha Villalba-Diebold; Jelpe Dadik; Felicia Okolo; Edwina Mang; Man Charurat
Journal:  Int J Gynaecol Obstet       Date:  2009-05-22       Impact factor: 3.561

7.  Estimating and projecting HIV prevalence and AIDS deaths in Tanzania using antenatal surveillance data.

Authors:  Geofrey R Somi; Mecky I N Matee; Roland O Swai; Eligius F Lyamuya; Japhet Killewo; Gideon Kwesigabo; Tuhuma Tulli; Titus K Kabalimu; Lucy Ng'ang'a; Raphael Isingo; Joel Ndayongeje
Journal:  BMC Public Health       Date:  2006-05-03       Impact factor: 3.295

8.  Population and antenatal-based HIV prevalence estimates in a high contracepting female population in rural South Africa.

Authors:  Brian D Rice; Jörg Bätzing-Feigenbaum; Victoria Hosegood; Frank Tanser; Caterina Hill; Till Barnighausen; Kobus Herbst; Tanya Welz; Marie-Louise Newell
Journal:  BMC Public Health       Date:  2007-07-18       Impact factor: 3.295

9.  Human Immunodeficiency Virus Infection Newly Diagnosed at Autopsy in New York City, 2008-2012.

Authors:  Chitra Ramaswamy; Tanya M Ellman; Julie Myers; Ann Madsen; Kent Sepkowitz; Colin Shepard
Journal:  Open Forum Infect Dis       Date:  2015-09-30       Impact factor: 3.835

Review 10.  High HIV prevalence and associated factors in a remote community in the Rwenzori region of Western Uganda.

Authors:  John Rubaihayo; Surat Akib; Ezekiel Mughusu; Andrew Abaasa
Journal:  Infect Dis Rep       Date:  2010-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.